Mitchell Mandel, MD
Dermatology · New York, NYNPI 1710076427
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $13,882 of the $15,691 with a category attached, or 88.5%. It is spread thinly across 42 manufacturers, the largest accounting for just 22.5% — the pattern of someone who eats at a lot of different presentations.
Across 482 payments — averaging $32.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merz North America, Inc.$4K
- Johnson & Johnson$2K
- Pfizer$1K
- Revance Therapeutics, Inc.$1K
- AbbVie$1K
- Arcutis Biotherapeutics, Inc.$1K
- plus $6K from 36 others
What the payments were for
- Travel & lodging$1,53210%
- Food & beverage$13,88288%
- Education$2782%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,691 in reported general payments places this provider in the 80th percentile of 1,151 dermatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tacrolimus | 22 | $3,845 |
| Pimecrolimus | 12 | $3,404 |
| Metronidazole | 42 | $1,893 |
| Fluticasone Propionate | 69 | $1,380 |
| Mupirocin | 140 | $1,152 |
| Ketoconazole | 63 | $1,097 |
| Fluocinonide | 34 | $951 |
| Clobetasol Propionate | 26 | $878 |
| Imiquimod | 20 | $649 |
| Triamcinolone Acetonide | 77 | $495 |
| Clindamycin Phosphate | 13 | $488 |
| ValacyclovirValacyclovir Hcl | 13 | $476 |
| CiclopiroxCiclopirox Olamine | 30 | $439 |
| ErythromycinErythromycin Base In Ethanol | 12 | $354 |
| Desonide | 13 | $291 |
Paid to pharmacies, not to this prescriber.
Other dermatology in New York
- Alexandra GolantNew York$3.6M
- David CohenNew York$3M
- Michael CameronNew York$2.6M
- Saakshi KhattriNew York$2.4M
- Amy WechslerNew York$2.4M
- Joshua ZeichnerNew York$2.1M
- Emma GuttmanNew York$1.7M
- George HanNew York$1.6M
- Amy SpizuocoNew York$1.3M
- Andrew AlexisNew York$834K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.